Loading blog post…
A science-based guide to omega-3 fatty acids for skin — how EPA and DHA reduce skin inflammation, evidence for eczema, psoriasis, and photoprotection, whether topical or oral is more effective, and dosing guidance.
· By MedSpot Editorial · 4 min read
Omega-3 fatty acids have one of the largest evidence bases of any supplement for systemic health — including cardiovascular protection, inflammation reduction, and brain function. Their skin-specific effects are supported by a distinct and meaningful body of research. Here's what the evidence actually shows for skin.
EPA (eicosapentaenoic acid): The primary anti-inflammatory omega-3 for skin. EPA is metabolized to the 3-series prostaglandins (PGE3) and 5-series leukotrienes — which are anti-inflammatory compared to the pro-inflammatory 2-series and 4-series produced from arachidonic acid. EPA also directly inhibits the enzyme COX-2 (cyclooxygenase-2), reducing inflammatory prostaglandin synthesis.
DHA (docosahexaenoic acid): The primary structural omega-3 in cell membranes. DHA increases membrane fluidity in keratinocytes and sebocytes, modulating how cells respond to UV and inflammatory signals. DHA also converts to resolvin D-series — pro-resolving mediators that actively turn off inflammation rather than just suppressing it.
ALA (alpha-linolenic acid): Plant-derived omega-3 found in flaxseed, chia, walnuts. The body can convert ALA to EPA and DHA, but conversion efficiency is low (typically <5–10% for EPA, <0.5% for DHA). ALA-rich plant oils are not equivalent to fish oil for skin-specific omega-3 effects.
Inflammation reduction: The EPA → 3-series prostaglandin pathway directly competes with the arachidonic acid → 2-series prostaglandin pathway. Higher EPA intake shifts this ratio, reducing inflammatory signaling in skin. This is directly relevant for inflammatory skin conditions: acne, eczema, psoriasis, and UV-induced photoaging.
Photoprotection: EPA has a specific photoprotective mechanism beyond general antioxidant activity: it reduces UV-induced immunosuppression. UV radiation suppresses local skin immune function — EPA supplementation partially counters this effect. Multiple human studies show EPA supplementation reduces UV-induced erythema (sunburn) at equivalent UV doses.
Sebum regulation: EPA reduces sebum production via inhibition of 5-LOX (5-lipoxygenase), reducing leukotriene B4 — a pro-inflammatory signaling molecule that drives sebocyte activity. This is a distinct mechanism from retinoids or spironolactone but with the same directional outcome.
Barrier function: DHA's structural integration into keratinocyte membranes improves membrane fluidity and signaling, supporting barrier function. Low omega-3 status correlates with higher TEWL in epidemiological studies.
Eczema: Birch et al. (2010, British Journal of Dermatology): Meta-analysis of 9 RCTs found omega-3 supplementation produced statistically significant improvement in eczema severity scores, though effect sizes were modest. Most effective in children and in studies using EPA + DHA rather than ALA alone.
Psoriasis: A 2014 Cochrane Review (Millsop et al.) found omega-3 supplementation improved psoriasis Area and Severity Index (PASI) scores in most included RCTs, with EPA specifically showing more consistent benefit than DHA alone.
Acne: Khayef et al. (2012, Lipids in Health and Disease): A 10-week RCT of omega-3 + antioxidant supplementation reduced inflammatory and non-inflammatory acne lesion counts significantly vs. control. Mechanism consistent with leukotriene B4 suppression.
Photoprotection: Rhodes et al. (2003, Journal of Investigative Dermatology): Human subjects supplemented with 4g EPA daily for 3 months showed significantly reduced UV-induced erythema (sunburn redness) and reduced UV-induced DNA damage markers. This is among the cleaner human evidence for omega-3 UV protection.
Anti-aging: Epidemiological data links higher omega-3 dietary intake to less photoaging. The Nurses' Health Study found higher fish intake correlated with less severe skin aging. Mechanistic evidence (inflammation reduction, UV protection) supports this association.
Oral supplementation has essentially all the clinical evidence. The anti-inflammatory effects operate systemically — changing the prostaglandin and leukotriene balance throughout the body including skin.
Topical omega-3 oils (flaxseed oil, fish oil, some seed oils): Can deliver ALA and EPA to the skin surface, where they integrate into keratinocyte membranes locally. Limited topical-specific clinical evidence, but mechanistically plausible for local barrier effects.
Practical answer: Oral supplementation is the evidence-backed approach for systemic skin conditions (eczema, psoriasis, acne, photoprotection). High-omega-3 oils applied topically (flaxseed, hemp seed) provide local barrier-supportive fatty acids without the systemic EPA/DHA effect.
Evidence-based doses from clinical trials:
Timeline: Consistent with other anti-inflammatory interventions — expect 8–12 weeks of supplementation before significant skin improvement.
Supplement quality matters:
Inflammatory skin conditions (eczema, psoriasis, acne): The primary evidence base. Omega-3 supplementation is a reasonable adjunct to conventional treatment.
Photoaging prevention: Patients spending significant time in the sun — omega-3's UV-protective and anti-inflammatory properties provide meaningful additive protection alongside SPF.
Dry, dehydrated skin with compromised barrier: DHA integration into cell membranes supports barrier function improvement over time.
Hormonal acne: EPA's leukotriene B4 suppression and sebum reduction are worth adding to a comprehensive approach.
Looking for skincare providers? Browse med spa and skincare providers on MedSpot →